Eltrombopag Tablets + Eltrombopag PfOS
Phase 3Completed 0 watching 0 views this week๐ Rising
77
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Purpura, Thrombocytopenic, Idiopathic
Conditions
Purpura, Thrombocytopenic, Idiopathic
Trial Timeline
Jun 18, 2013 โ Jul 4, 2017
NCT ID
NCT02201290About Eltrombopag Tablets + Eltrombopag PfOS
Eltrombopag Tablets + Eltrombopag PfOS is a phase 3 stage product being developed by Novartis for Purpura, Thrombocytopenic, Idiopathic. The current trial status is completed. This product is registered under clinical trial identifier NCT02201290. Target conditions include Purpura, Thrombocytopenic, Idiopathic.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02201290 | Phase 3 | Completed |
Competing Products
20 competing products in Purpura, Thrombocytopenic, Idiopathic